Hledání v detailu akcií
Top akcie
NázevNávštěvy
19 188
879
854
807
610
539
528
384
378
374
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN82,8-0,24
Msft-0,72
Nokia5,0645,0921,11
IBM0,02
DCX57,5657,57-0,31
PFE0,58
23.6.2018 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 22.6.2018
Applied Gen Technlg (NASDAQ Cons)
Závěr k 22.6.2018 Změna (%) Změna (USD) Objem obchodů (ks)
4,35 -1,14 -0,05 53 374
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 24.6.2018
Popis společnosti
Obecné informace
Název společnostiApplied Genetic Technologies Corp
TickerAGTC
Kmenové akcie:Ordinary Shares
RICAGTC.O
ISINUS03820J1007
Poslední známé roční výsledky30.6.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 30.6.2017 72
Akcie v oběhu k 2.5.2018 18 110 536
Počet akcionářů k 30.6.2017 35
MěnaUSD
Kontaktní informace
Ulice14193 Nw 119Th Terrace, Suite #10
MěstoALACHUA
PSČ32615
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 864 622 204
Fax13026365454

Business Summary: Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
Financial Summary: BRIEF: For the nine months ended 31 March 2018, Applied Genetic Technologies Corp revenues decreased 40% to $18.8M. Net loss before extraordinary items totaled $15.5M vs. income of $3.6M. Revenues reflect Grant and other revenue decrease of 74% to $43K. Net loss reflects General and administrative and other - B increase of 49% to $4.6M (expense), Employee-Related Costs increase of 34% to $4.2M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 24.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardScott Koenig64
President, Chief Executive Officer, DirectorSusan Washer56
Chief Financial OfficerWilliam Sullivan467.8.20177.8.2017
Senior Vice President, Chief Medical OfficerJeffrey Chulay70
Chief Scientific OfficerMark Shearman551.6.20151.6.2015
Vice President - Clinical Development OperationsKaren Carroll-14.6.201814.6.2018
Vice president and chief business officerStephen Potter6028.1.201528.1.2015
Vice President - Clinical Research and Medical AffairsLanita Scott-14.6.201814.6.2018
General CounselAndrew Ashe492.8.20172.8.2017
Chief Medical OfficerMichael Goldstein501.12.20161.12.2016